Artikel
A biomarker benchmark study for monitoring SLE activity: Only SIGLEC-1 and C3 are better than flipping a coin
Suche in Medline nach
Autoren
Veröffentlicht: | 12. September 2014 |
---|
Gliederung
Text
Background: To benchmark three biomarkers for interferon activity with standard- and state of the art-biomarkers for correct classification of increased or decreased disease activity (DA) in systemic lupus erythematosus (SLE).
Methods: IFNα (dissociation-enhanced lanthanide fluorescent immunoassay), IFNγ-inducible protein 10 (IP-10) (ELISA) and sialic acid-binding Ig-like lectin 1 (SIGLEC-1) (flow cytometry) were serial measured in 26 lupus patients (77 total visits, 108 differential visits) and compared with serum titres of Anti-dsDNA (ELISA and radioimmunoassay), Anti-dsDNA-NcX ELISA, Anti-Nuc ELISA, and complement C3 and C4. DA was evaluated using the British Isles Lupus Assessment Group 2004 Index (BILAG-2004) and were compared longitudinally to biomarker behaviours.
Results: 25 differential visits with an increase in BILAG-2004 >3 and 22 differential visits with a decrease in BILAG- 2004 <-3 were assessed. 61 differential visits with stable disease activity were excluded because of severeal reasons (e.g. impossible discrimation between unsensitivity of a biomarker and correct classification). Correct classification rates for increased and decreased disease activities were obtained for SIGLEC-1 (76% vs 50%), C3 (48% vs. 59%), Anti-Nuc ELISA (56% vs. 27%), Anti-dsDNA-NcX ELISA (52% vs 32%), C4 (24% vs 50%), Anti-dsDNA ELISA (36% vs 31%), IFNα (32% vs 32%), IP-10 (28% vs 36%) and Farr-assay (16% vs 4%).
Conclusion: This is the first study in SLE that benchmark biomarkers for the classification of increased or decreased disease activity. Only SIGLEC-1 (63.8 %) and C3 (53.2 %) demonstrated a moderate rate of cumulative correct classifications. Despite of these results should be confirmed in a larger cohort, these data suggest that several new and traditional biomarkers are overestimated in their clinical usefulness.